COVID-19 Treatment Guidelines

Patient Assessment and Eligibility

• The Infectious Diseases Society of America (IDSA) acknowledges that practical considerations of accessibility and timeliness of treatment are paramount for prescribing Paxlovid based on a positive at-home COVID-19 test, without requiring confirmatory laboratory testing 1
• Home antigen tests have high specificity (97.9%), meaning a positive result is likely a true positive and doesn't require confirmation 1, 2

Treatment Initiation and Dosage

• Paxlovid must be initiated within 5 days of symptom onset for maximum effectiveness, although the exact timing is not specified in the provided citations, the standard dosing is nirmatrelvir 300 mg with ritonavir 100 mg, taken together twice daily for 5 days 1

Diagnostic Considerations

• Home tests have lower sensitivity than laboratory tests, particularly early in infection, and if clinical suspicion remains high despite a negative test, consider laboratory testing 2
• False negatives with home testing can occur, and clinicians should be aware of this limitation when interpreting test results 2

Medication Interactions and Safety

• Ritonavir is a potent CYP3A4 inhibitor and can interact with numerous medications, a thorough medication review is essential before prescribing Paxlovid 2